Physician profile
Barbara Nylander
NPI 1003819046
$2,760.45
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $219 · 2021: $739 · 2022: $420 · 2023: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $670.07 | 2019-2021 | |
| Aspira Women'S Health INC | $279.82 | 2021-2022 | |
| Abbvie INC. | $252.37 | 2019-2023 | |
| Pfizer INC. | $175.80 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $146.75 | 2019 | |
| Mylan Pharmaceuticals INC. | $140.63 | 2019-2022 | |
| Millicent US INC | $114.03 | 2021-2023 | Femring, Intrarosa |
| Channel Medsystems, INC. | $95.82 | 2022-2023 | |
| Duchesnay USA Incorporated | $77.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.18 | 2019-2020 | |
| Avion Pharmaceuticals | $71.08 | 2019-2023 | Balcoltra |
| Ascend Therapeutics US, LLC | $62.18 | 2022-2023 | |
| Therapeuticsmd, INC. | $61.18 | 2021-2022 | |
| Myovant Sciences INC. | $58.16 | 2021-2022 | |
| Coopersurgical, INC. | $45.65 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $40.49 | 2021 | |
| Allergan, INC. | $40.48 | 2019-2020 | |
| Shield Therapeutics INC | $39.06 | 2022-2023 | Accrufer |
| Mayne Pharma Commercial LLC | $37.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.14 | 2019 | |
| Olympus America INC. | $31.01 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $29.28 | 2019 | |
| Ethicon US, LLC | $25.00 | 2021 | |
| Amgen INC. | $23.98 | 2019-2020 | |
| Novo Nordisk INC | $23.29 | 2023 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $18.26 | 2019 | |
| Avanos Medical | $17.68 | 2019 | |
| Axonics, INC. | $14.95 | 2021 | |
| Minerva Surgical, INC | $14.83 | 2020 | |
| Radius Health, INC. | $14.09 | 2019 | |
| Virtus Pharmaceuticals LLC | $12.68 | 2021 | |
| Roche Diagnostics Corporation | $12.23 | 2019 | |
| Lupin INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Nylander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.